Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Summarising the use of thiazolidinediones with insulin

Anthony H Barnett

Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS. UK, anthony.barnett{at}heartofengland.nhs.uk

Both insulin resistance and pancreatic beta-cell function normally contribute to the development of type 2 diabetes, with the latter also responsible for the progression of the disease. Successful management inevitably requires therapy that addresses both underlying defects. Clinical trials support the use of agents with complementary mechanisms of action. The major therapeutic effect of the thiazolidinediones in type 2 diabetes is improvement of insulin sensitivity and they are thus ideally suited for combination therapy with insulin, although they can also be used as monotherapy or in dual or triple oral agent therapy. In addition to improving glycaemic control, the thiazolidinediones have favourable effects on a number of cardiovascular risk factors and may reduce the risk of long-term diabetes-related complications independent of their effects on glycaemic control. Combination therapy of a thiazolidinedione with insulin is no longer contraindicated in Europe, and this combination can provide improvements in glycaemic control that are additive to the effects of insulin alone.

Key Words: combination therapy • insulin • pioglitazone • rosiglitazone • thiazolidinedione • type 2 diabetes mellitus.

References

  • Haffner SM, Mykkanen L., Festa A., Burke JP, Stern MP Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.[Abstract]
  • Nesto RW The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4(suppl 6):S11-S18.[Medline] [Order article via Infotrieve]
  • Smiley T., Oh P., Shane LG The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes-a systematic review. Can J Cardiol 2001;17:797-805.[Web of Science][Medline] [Order article via Infotrieve]
  • Bonora E., Calcaterra F., Lombardi S. et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-9. Care
  • Nathan DM, Buse JB, Davidson MB et al. Management of D hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006;49:1711-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kahn CR, Chen L., Cohen SE Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000;106:1305-07.[Web of Science][Medline] [Order article via Infotrieve]
  • Lebovitz HE, Dole JF, Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.[Abstract/Free Full Text]
  • Raskin P., Rendell M., Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.[Abstract/Free Full Text]
  • Aronoff S., Rosenblatt S., Braithwaite S. et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11.[Abstract/Free Full Text]
  • Einhorn D., Rendell M., Rosenzweig J. et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kipnes MS, Krosnick A., Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.[Web of Science][Medline] [Order article via Infotrieve]
  • Rosenstock J., Goldstein B., Vinik AI et al. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (> 60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. Diabetes Obes Metab 2006;8:49-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gomez-Perez FJ, Fanghanel-Salmon G., Barbosa JA et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Garber AJ, Schweizer A., Baron MA, Rochotte E., Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosenstock J., Baron MA, Camisasca RP, Cressier F., Couturier A., Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosenstock J., Baron MA, Dejager S., Mills D., Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23.[Abstract/Free Full Text]
  • Rosenstock J., Brazg R., Andryuk PJ, Lu K., Stein P., Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tran MT, Navar MD, Davidson MB Comparison of the glycemic effects of rosiglitz one and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care 2006;29:1395-6.[Free Full Text]
  • Charbonnel B., Scheen A. Pioglita zone in triple oral therapy: long-term glycemic results from PROactive. Diabetes in 2006;55(suppl 1):A135.
  • Scheen A., Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive. Diabetes 2006;55(suppl 1):A134.
  • Rosenstock J., Rood J., Cobitz A., Huang C., Garber A. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 2006;8:643-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deeks ED, Scott LJ Pioglitazone/metformin. Drugs 2006;66:1863-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Actos® (pioglitazone) licence change gives new treatment option to patients with type 2 diabetes. Takeda UK Ltd press release, 9 Nov 2006. Available from: http://dave.md/s/PressReleases/Takeda110906.pdf.
  • Granberry MC, Fonseca VA Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005;5:201-09.[CrossRef][Medline] [Order article via Infotrieve]
  • Bell DSH. Dyslipidemia in type 2 diabetes and the effects of thiazolidinediones. Endocrinologist 2003;13:496-504.[CrossRef][Web of Science]
  • Haffner S., Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.[Abstract/Free Full Text]
  • Mohanty P., Aljada A., Ghanim H. et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.[Abstract/Free Full Text]
  • Pfutzner A., Marx N., Lubben G. et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31.[Abstract/Free Full Text]
  • Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schmitz O. Influence of rosiglitazone treatment on A-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003;88:3794-800.[Abstract/Free Full Text]
  • Xiang A., Peters R., Kjos S. et al. Effect of pioglitazone on pancreatic A-cell function and diabetes risk in hispanic women with gestational diabetes. Diabetes 2006;55:517-22.[Abstract/Free Full Text]
  • DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.[CrossRef][Medline] [Order article via Infotrieve]
  • Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.[Abstract/Free Full Text]
  • Raskin P., Rendell M., Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.[Abstract/Free Full Text]
  • Garg R., Gopal J., Jones GR Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone. J Diabetes Complications 2007;21:1-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Raz I., Mouritzen U., Vaz J., Hershkovitz T., Wainstein J., Harman-Boehm I. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rosenstock J., Einhorn D., Hershon K., Glazer NB, Yu S.; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Davidson JA, Perez A., Zhang J., the Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006;8:164-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mattoo V., Eckland D., Widel M. et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27:554-67.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Martens FM, Visseren FL, Lemay J. et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Huang A., Raskin P. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Treat Endocrinol 2005;4:205-20.[CrossRef][Medline] [Order article via Infotrieve]
  • Nesto RW, Bell D., Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.[Free Full Text]
  • Takeda UK Ltd. Actos tablets. Summary of Product Characteristics, 2007.
  • GlaxoSmithKline UK. Avandia 4 mg and 8 mg tablets. Summary of Product Characteristics, 2006.
  • Lebovitz HE Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18(suppl 2):S23-S29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 2, 75-80 (2007)
DOI: 10.1177/14746514070070020501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?